Data-driven analysis backed by 1,400+ primary-sourced biopharma transactions. Licensing benchmarks, negotiation strategies, and market intelligence.
Ipsen has executed 8 deals since 2017, with a sharp pivot toward hematology driving its most recent — and largest — transactions. Here's what their deal activity tells BD teams, founders, and investors about where Ipsen is heading and how to position assets accordingly.
The median upfront for a Phase 2 monoclonal antibody metabolic acquisition now sits at $342.5M — a number that would have been unthinkable outside oncology five years ago. Here's what's driving the premiums, how the biggest deals were structured, and what your term sheet should look like.
The median upfront for a Phase 2 small molecule immunology acquisition just hit $342.5M — and the total deal value ceiling has blown past $3.5B. We break down the benchmark data, deconstruct the five deals defining this market, and lay out what BD teams and founders need to negotiate from a position of strength.
The median upfront for a Phase 2 bispecific antibody neurology acquisition now sits at $342.5M — a number that would have been unthinkable five years ago. We break down the deal terms, deconstruct the comparable transactions, and give you a negotiation playbook backed by verified benchmarks.
The median upfront for a peptide women's health licensing deal at Phase 2 has hit $342.5M — a number that would have been unthinkable three years ago. Here's why the economics shifted, what the comparable deals actually tell us, and how to negotiate from either side of the table.
The median upfront for a Phase 2 CAR-T (hematologic) gastroenterology licensing deal has hit $342.5M — a number that would have been unthinkable three years ago. Here's what's driving the inflation, how the biggest deals were structured, and what it means for your next term sheet.
The median upfront for a Phase 2 PROTAC dermatology licensing deal now sits at $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest comparable deals, and offer a tactical negotiation playbook for founders and BD teams navigating this white-hot modality.
The median upfront for a Phase 2 mRNA ophthalmology licensing deal has hit $342.5M — a number that would have been unthinkable three years ago. Here's the benchmark data, the deal structures behind it, and what it means for your next term sheet.
The median upfront payment for a Phase 2 RNAi infectious disease licensing deal now sits at $342.5M — a figure that would have been inconceivable five years ago. We break down the benchmark data, deconstruct the comparable deals, and provide a tactical negotiation playbook for both founders and BD professionals.
The median upfront for a Phase 2 cell therapy hematology licensing deal has hit $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest comparable transactions, and deliver a tactical negotiation playbook for both biotech founders and pharma BD teams.
The median upfront for a Phase 2 gene therapy rare disease licensing deal now sits at $342.5M — a number that would have been unthinkable five years ago. Here's what's driving those economics, how the biggest recent deals were structured, and what BD teams and founders need to know before they sit down at the table.
The median upfront payment for a Phase 2 monoclonal antibody cardiovascular licensing deal now sits at $342.5M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct five real comparable deals, and deliver the negotiation playbook BD teams and founders actually need.
The median upfront payment for a small molecule metabolic licensing deal at phase 2 is now $120M — but the real story is in the zero-upfront mega-deals reshaping the market. We break down the benchmarks, deconstruct the biggest 2024–2025 comps, and give you the negotiation playbook.
The median upfront for a Phase 2 bispecific antibody immunology licensing deal has hit $340M — a number that would have been laughable five years ago. Here's what's driving the inflation, how the biggest 2025 deals were structured, and what your next term sheet should look like.
The median upfront for a Phase 2 ADC neurology licensing deal now sits at $120M, with total deal values stretching to $2.5B. We break down the benchmark data, deconstruct the biggest recent neurology deals, and deliver a tactical negotiation playbook for both founders and BD professionals.
The median upfront for an anti-VEGF oncology licensing deal at Phase 2 has hit $340M — a number that would have been a total deal value five years ago. We break down the benchmark data, deconstruct the five largest comparable deals, and give you the negotiation playbook your deal committee actually needs.
The median upfront for a Phase 2 CAR-T (hematologic) women's health licensing deal now sits at $120M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct comparable deals, and deliver the negotiation playbook BD teams actually need.
The median upfront for a Phase 2 PROTAC gastroenterology licensing deal has hit $340M — a number that would have been unthinkable three years ago. Here's what's driving the premiums, how the biggest deals were structured, and what BD teams need to know before the next term sheet lands.
The median upfront for an mRNA dermatology licensing deal at Phase 2 is now $340M — a number that would have been unthinkable three years ago. Here's the full benchmark breakdown, comparable deal analysis, and a negotiation playbook built for the people actually sitting across the table.
The median upfront for a Phase 2 RNAi ophthalmology licensing deal has hit $340M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and give you the negotiation playbook for both sides of the table.
The median upfront for a Phase 2 cell therapy infectious disease licensing deal has hit $340M — a number that would have been absurd five years ago. Here's the full benchmark breakdown, deal deconstructions, and a negotiation playbook for both founders and BD professionals.
The median upfront for a Phase 2 gene therapy hematology licensing deal is now $340M — a number that would have been unthinkable three years ago. We break down the benchmark data, deconstruct the biggest comparable deals, and deliver a tactical negotiation playbook for both founders and BD teams.
The median upfront payment for a Phase 2 monoclonal antibody rare disease licensing deal now sits at $340M — a number that would have been unthinkable five years ago. Here's what's driving the inflation, how the smartest deal teams are structuring terms, and where the market is heading in 2025–2026.
The median upfront for a Phase 2 small molecule cardiovascular licensing deal now sits at $340M — a figure that would have been unthinkable five years ago. We break down the benchmark data, deconstruct five real deals, and deliver the negotiation playbook BD teams and founders actually need.
GSK is acquiring Nuvalent, the ROS1/ALK-focused lung cancer biotech, for $10.6 billion — a deal that blows past every standard Phase 2 oncology acquisition benchmark by an order of magnitude. Here's what the premium signals about where Big Pharma is placing its bets on small molecule targeted oncology in 2026.
Get data-driven deal terms for any therapeutic area, modality, and clinical phase. Powered by 1,400+ primary-sourced biopharma transactions.
Try Solidus
